NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
Publication
, Journal Article
Mesa, RA; Jamieson, C; Bhatia, R; Deininger, MW; Fletcher, CD; Gerds, AT; Gojo, I; Gotlib, J; Gundabolu, K; Hobbs, G; McMahon, B; Mohan, SR ...
Published in: Journal of the National Comprehensive Cancer Network : JNCCN
October 2017
Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Journal of the National Comprehensive Cancer Network : JNCCN
DOI
EISSN
1540-1413
ISSN
1540-1405
Publication Date
October 2017
Volume
15
Issue
10
Start / End Page
1193 / 1207
Related Subject Headings
- Treatment Outcome
- Risk Assessment
- Oncology & Carcinogenesis
- Myeloproliferative Disorders
- Humans
- Combined Modality Therapy
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Mesa, R. A., Jamieson, C., Bhatia, R., Deininger, M. W., Fletcher, C. D., Gerds, A. T., … Sundar, H. (2017). NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. Journal of the National Comprehensive Cancer Network : JNCCN, 15(10), 1193–1207. https://doi.org/10.6004/jnccn.2017.0157
Mesa, Ruben A., Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Christopher D. Fletcher, Aaron T. Gerds, Ivana Gojo, et al. “NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.” Journal of the National Comprehensive Cancer Network : JNCCN 15, no. 10 (October 2017): 1193–1207. https://doi.org/10.6004/jnccn.2017.0157.
Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, et al. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. Journal of the National Comprehensive Cancer Network : JNCCN. 2017 Oct;15(10):1193–207.
Mesa, Ruben A., et al. “NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.” Journal of the National Comprehensive Cancer Network : JNCCN, vol. 15, no. 10, Oct. 2017, pp. 1193–207. Epmc, doi:10.6004/jnccn.2017.0157.
Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podoltsev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. Journal of the National Comprehensive Cancer Network : JNCCN. 2017 Oct;15(10):1193–1207.
Published In
Journal of the National Comprehensive Cancer Network : JNCCN
DOI
EISSN
1540-1413
ISSN
1540-1405
Publication Date
October 2017
Volume
15
Issue
10
Start / End Page
1193 / 1207
Related Subject Headings
- Treatment Outcome
- Risk Assessment
- Oncology & Carcinogenesis
- Myeloproliferative Disorders
- Humans
- Combined Modality Therapy
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis